The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease.
Adolescent
Arteritis
/ drug therapy
Child
Child, Preschool
Coronary Artery Disease
/ drug therapy
Female
Humans
Immunoglobulins, Intravenous
/ therapeutic use
Immunologic Factors
/ therapeutic use
Infant
Inflammation Mediators
/ metabolism
Male
Mucocutaneous Lymph Node Syndrome
/ drug therapy
Retrospective Studies
Time Factors
Treatment Outcome
American Heart Association
C-reactive protein
Coronary artery abnormalities
Intravenous immunoglobulin
Kawasaki disease
Journal
Pediatric rheumatology online journal
ISSN: 1546-0096
Titre abrégé: Pediatr Rheumatol Online J
Pays: England
ID NLM: 101248897
Informations de publication
Date de publication:
31 Jul 2019
31 Jul 2019
Historique:
received:
06
04
2019
accepted:
10
07
2019
entrez:
2
8
2019
pubmed:
2
8
2019
medline:
11
2
2020
Statut:
epublish
Résumé
In the last decade, incomplete Kawasaki disease (KD), intravenous immunoglobulin (IVIG) non-response and coronary artery abnormalities (CAA) have experienced the increasing trends in China. In addition, the enhancement of pediatricians' awareness may also raise the diagnostic rate of incomplete KD and stimulate more aggressive initial therapy in the acute episode of KD. Given this background, we hypothesize that the time option of IVIG treatment should be in parallel with peak time of systemic inflammation; either earlier or later IVIG treatment may affect the clinical classification, therapeutic responsiveness and CAA occurrence in KD patients. Therefore, the major objective of the present study is to identify whether the time option of IVIG treatment could be associated with the clinical classification, therapeutic responsiveness and CAA occurrence in the acute episode of KD. A total of 153 children with KD were recruited between July 2015 and May 2018. All patients received the standard therapy of KD, including a single infusion of IVIG (2 g/kg) and aspirin (30-50 mg/kg/d). Blood samples were collected from all subjects within 24 h pre-IVIG treatment, respectively. Echocardiography was performed during the period from 2 days to 14 days after IVIG treatment. (1) The clinical classification presented no significant heterogenicity among different treatment time (x The time option of IVIG treatment is associated with therapeutic responsiveness and CAA but not with clinical classification in the acute episode of KD.
Sections du résumé
BACKGROUND
BACKGROUND
In the last decade, incomplete Kawasaki disease (KD), intravenous immunoglobulin (IVIG) non-response and coronary artery abnormalities (CAA) have experienced the increasing trends in China. In addition, the enhancement of pediatricians' awareness may also raise the diagnostic rate of incomplete KD and stimulate more aggressive initial therapy in the acute episode of KD. Given this background, we hypothesize that the time option of IVIG treatment should be in parallel with peak time of systemic inflammation; either earlier or later IVIG treatment may affect the clinical classification, therapeutic responsiveness and CAA occurrence in KD patients. Therefore, the major objective of the present study is to identify whether the time option of IVIG treatment could be associated with the clinical classification, therapeutic responsiveness and CAA occurrence in the acute episode of KD.
MATERIALS AND METHODS
METHODS
A total of 153 children with KD were recruited between July 2015 and May 2018. All patients received the standard therapy of KD, including a single infusion of IVIG (2 g/kg) and aspirin (30-50 mg/kg/d). Blood samples were collected from all subjects within 24 h pre-IVIG treatment, respectively. Echocardiography was performed during the period from 2 days to 14 days after IVIG treatment.
RESULTS
RESULTS
(1) The clinical classification presented no significant heterogenicity among different treatment time (x
CONCLUSIONS
CONCLUSIONS
The time option of IVIG treatment is associated with therapeutic responsiveness and CAA but not with clinical classification in the acute episode of KD.
Identifiants
pubmed: 31366406
doi: 10.1186/s12969-019-0352-3
pii: 10.1186/s12969-019-0352-3
pmc: PMC6668082
doi:
Substances chimiques
Immunoglobulins, Intravenous
0
Immunologic Factors
0
Inflammation Mediators
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
53Références
J Korean Med Sci. 2004 Aug;19(4):501-4
pubmed: 15308837
Pediatrics. 2004 Dec;114(6):1708-33
pubmed: 15574639
Circulation. 2006 Jun 6;113(22):2606-12
pubmed: 16735679
N Engl J Med. 2007 Feb 15;356(7):663-75
pubmed: 17301297
Genome Biol. 2007;8(12):R261
pubmed: 18067656
Arthritis Rheum. 2009 Jul;60(7):2131-41
pubmed: 19565485
Pediatrics. 2010 Feb;125(2):e234-41
pubmed: 20100771
J Clin Lab Anal. 2010;24(6):385-8
pubmed: 21089168
Circ Cardiovasc Genet. 2011 Feb;4(1):16-25
pubmed: 21127203
Ann Trop Paediatr. 2011;31(2):109-14
pubmed: 21575314
Pediatr Infect Dis J. 2011 Dec;30(12):1022-6
pubmed: 21817952
Pediatr Cardiol. 2012 Feb;33(2):272-9
pubmed: 21965088
Pediatrics. 2012 Feb;129(2):e291-7
pubmed: 22250032
ScientificWorldJournal. 2012;2012:210382
pubmed: 22454602
Eur J Immunol. 2012 Aug;42(8):2121-31
pubmed: 22585560
Clin Exp Rheumatol. 2013 Jan-Feb;31(1):149-53
pubmed: 23324126
Arch Dis Child. 2014 Jan;99(1):74-83
pubmed: 24162006
N Engl J Med. 1986 Aug 7;315(6):341-7
pubmed: 2426590
Pediatr Neonatol. 2014 Oct;55(5):387-92
pubmed: 24636168
Genes Immun. 2014 Dec;15(8):534-42
pubmed: 25101798
Exp Ther Med. 2015 Jul;10(1):357-361
pubmed: 26170962
Pediatr Infect Dis J. 2016 Jan;35(1):7-12
pubmed: 26372452
J Trop Pediatr. 2016 Apr;62(2):86-93
pubmed: 26884440
Exp Ther Med. 2016 Aug;12(2):1220-1224
pubmed: 27446347
Circ Cardiovasc Genet. 2016 Dec;9(6):559-568
pubmed: 27879314
Circulation. 2017 Apr 25;135(17):e927-e999
pubmed: 28356445
J Pediatr. 2017 Jun;185:112-116.e1
pubmed: 28408126
Clin Chim Acta. 2017 Aug;471:76-80
pubmed: 28526535
Oncotarget. 2017 Apr 29;8(33):54357-54363
pubmed: 28903347
Pediatr Int. 2018 Apr;60(4):334-341
pubmed: 29292568
Postgrad Med. 2018 May;130(4):442-447
pubmed: 29745742
Clin Rheumatol. 2019 Apr;38(4):1099-1107
pubmed: 30523553
Sci Rep. 2019 Feb 11;9(1):1722
pubmed: 30742060
J Am Coll Cardiol. 1986 Feb;7(2):355-60
pubmed: 3944354
J Pediatr. 1993 Apr;122(4):538-42
pubmed: 8463897